Tables
TABLE 1 HISTORICAL TREND OF ED VOLUNTEERS IN DIFFERENT PHASES 26
TABLE 2 ERECTILE DYSFUNCTION CLINICAL TRIALS IN THE US SPREAD ACROSS THE GLOBE IN 2017 27
TABLE 3 PIPELINE SNAPSHOT IN KEY THERAPY AREAS 27
TABLE 4 ETHICAL ISSUES FACED BY VARIOUS RESEARCH INSTITUTES AND LABS AT DIFFERENT PHASES 30
TABLE 5 STEM CELL RESEARCH POLICIES IN AMERICAS 30
TABLE 6 STEM CELL RESEARCH POLICIES IN EUROPE 31
TABLE 7 STEM CELL RESEARCH POLICIES IN APAC 31
TABLE 8 VIAGRA SALES 36
TABLE 9 CIALIS SALES 37
TABLE 10 LEVITRA SALES 38
TABLE 11 STENDRA/SPEDRA SALES 38
TABLE 12 MEN AND ERECTILE DYSFUNCTION STATISTICS 42
TABLE 13 RATE OF ERECTILE DYSFUNCTION AT DIFFERENT AGE GROUPS 51
TABLE 14 OBSERVATIONAL STUDY PERFORMED ON CHINA AND INDIA 52
TABLE 15 ERECTION HARDNESS SCORE (EHS) 54
TABLE 16 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET REVENUE BY REGIONS FORECAST' 2018-2024 ($MILLION) 60
TABLE 17 DRO (NORTH AMERICA) 62
TABLE 18 DRO (EUROPE) 65
TABLE 19 DRO (APAC) 68
TABLE 20 DRO (REST OF THE WORLD) 71
TABLE 21 COMPETITIVE STRUCTURE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION MARKET 2017 74
TABLE 22 COMPETITIVE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET 76
TABLE 23 PFIZER' INC.: PRODUCT OFFERINGS 77
TABLE 24 PFIZER INC.: RECENT DEVELOPMENTS 77
TABLE 25 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 82
TABLE 26 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 82
TABLE 27 BAYER AG: OFFERINGS 87
TABLE 28 BAYER AG: RECENT DEVELOPMENTS 87
TABLE 29 APRICUS BIOSCIENCES' INC.: OFFERINGS 93
TABLE 30 APRICUS BIOSCIENCES' INC.: RECENT DEVELOPMENTS 93
TABLE 31 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): OFFERINGS 98
TABLE 32 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): RECENT DEVELOPMENTS 98
TABLE 33 VIVUS' INC: OFFERINGS 103
TABLE 34 VIVUS' INC: RECENT DEVELOPMENTS 103
TABLE 35 AQUESTIVE THERAPEUTICS: SNAPSHOT 109
TABLE 36 ASTELLAS PHARMA INC.: SNAPSHOT 110
TABLE 37 BIOLAB FARMACEUTICA: SNAPSHOT 111
TABLE 38 BIOPHARM GMBH: SNAPSHOT 113
TABLE 39 FUTURA MEDICAL PLC: SNAPSHOT 114
TABLE 40 IX BIOPHARMA LTD.: SNAPSHOT 115
TABLE 41 SK CHEMICALS CO. LTD.: SNAPSHOT 116
LIST OF FIGURE
Tables
TABLE 1 HISTORICAL TREND OF ED VOLUNTEERS IN DIFFERENT PHASES 26
TABLE 2 ERECTILE DYSFUNCTION CLINICAL TRIALS IN THE US SPREAD ACROSS THE GLOBE IN 2017 27
TABLE 3 PIPELINE SNAPSHOT IN KEY THERAPY AREAS 27
TABLE 4 ETHICAL ISSUES FACED BY VARIOUS RESEARCH INSTITUTES AND LABS AT DIFFERENT PHASES 30
TABLE 5 STEM CELL RESEARCH POLICIES IN AMERICAS 30
TABLE 6 STEM CELL RESEARCH POLICIES IN EUROPE 31
TABLE 7 STEM CELL RESEARCH POLICIES IN APAC 31
TABLE 8 VIAGRA SALES 36
TABLE 9 CIALIS SALES 37
TABLE 10 LEVITRA SALES 38
TABLE 11 STENDRA/SPEDRA SALES 38
TABLE 12 MEN AND ERECTILE DYSFUNCTION STATISTICS 42
TABLE 13 RATE OF ERECTILE DYSFUNCTION AT DIFFERENT AGE GROUPS 51
TABLE 14 OBSERVATIONAL STUDY PERFORMED ON CHINA AND INDIA 52
TABLE 15 ERECTION HARDNESS SCORE (EHS) 54
TABLE 16 GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET REVENUE BY REGIONS FORECAST' 2018-2024 ($MILLION) 60
TABLE 17 DRO (NORTH AMERICA) 62
TABLE 18 DRO (EUROPE) 65
TABLE 19 DRO (APAC) 68
TABLE 20 DRO (REST OF THE WORLD) 71
TABLE 21 COMPETITIVE STRUCTURE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION MARKET 2017 74
TABLE 22 COMPETITIVE ANALYSIS OF GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET 76
TABLE 23 PFIZER' INC.: PRODUCT OFFERINGS 77
TABLE 24 PFIZER INC.: RECENT DEVELOPMENTS 77
TABLE 25 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 82
TABLE 26 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 82
TABLE 27 BAYER AG: OFFERINGS 87
TABLE 28 BAYER AG: RECENT DEVELOPMENTS 87
TABLE 29 APRICUS BIOSCIENCES' INC.: OFFERINGS 93
TABLE 30 APRICUS BIOSCIENCES' INC.: RECENT DEVELOPMENTS 93
TABLE 31 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): OFFERINGS 98
TABLE 32 MYLAN N.V. (MEDA PHARMACEUTICALS INC.): RECENT DEVELOPMENTS 98
TABLE 33 VIVUS' INC: OFFERINGS 103
TABLE 34 VIVUS' INC: RECENT DEVELOPMENTS 103
TABLE 35 AQUESTIVE THERAPEUTICS: SNAPSHOT 109
TABLE 36 ASTELLAS PHARMA INC.: SNAPSHOT 110
TABLE 37 BIOLAB FARMACEUTICA: SNAPSHOT 111
TABLE 38 BIOPHARM GMBH: SNAPSHOT 113
TABLE 39 FUTURA MEDICAL PLC: SNAPSHOT 114
TABLE 40 IX BIOPHARMA LTD.: SNAPSHOT 115
TABLE 41 SK CHEMICALS CO. LTD.: SNAPSHOT 116
